

viral HEPATITIS

11TH AUSTRALASIAN CONFERENCE

NO ONE LEFT BEHIND

CONFERENCE HANDBOOK

13 - 15 AUGUST 2018
ADELAIDE CONVENTION CENTRE

 **@ASHMMEDIA | #VH18**

THANK YOU TO OUR SPONSORS & SUPPORTERS

MAJOR SPONSORS & SUPPORTERS



Platinum Sponsor



Destination Supporter



Silver Sponsor



Bronze Sponsor

COLLABORATING ORGANISATIONS



Supporting the HIV, Viral Hepatitis
and Sexual Health Workforce



CONFERENCE ENVIRONMENT POLICY

ASHM Conference and Events
Division implements a waste-
reduction policy that addresses:

- Reduce, Reuse, Recycle. This is done before, during and after each conference.
- ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
- ASHM Conference & Events Division will endeavor to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.

ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

CONTENTS

Invited Speakers	▶ 3
Floor Plans and Maps	▶ 6
Exhibition Directory	▶ 8
Program	▶ 11
Poster Listing	▶ 31

NATIONAL OFFICE

A Locked Mail Bag 5057
Darlinghurst NSW 1300, Australia

T +61 2 8204 0770

E conference@ashm.org.au

W www.ashm.org.au

ABN: 48 264 545 457

CFN: 17788

© ASHM 2018

Design and layout by Rachel Lincoln

Printed by TTR Print Management

Hear Hep C stories at

SPREAD THECURE .COM.AU



TO FIND OUT
MORE ABOUT
TREATMENT
OPTIONS FOR
HEP C, VISIT
THE MSD STAND

PROUDLY SUPPORTED BY



Copyright © 2018 Merck Sharp & Dohme Corp a subsidiary of Merck & Co. Inc., Kenilworth, New Jersey, USA. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited, Level 1, Building A, 26 Talavera Rd, Macquarie Park, NSW 2113 Australia. INFC-1250735-0011. First issued June 2018. ZEP0171.

INTERNATIONAL SPEAKERS



MEHLIKA TOY

*PhD, DSc, Stanford
University School of
Medicine, USA*



**MICHAEL
NINBURG**

*President, World Hepatitis
Alliance, USA*



**SUNIL
SOLOMON**

*Associate Professor of
Medicine, Johns Hopkins
University School of
Medicine, Baltimore, USA*

LOCAL SPEAKERS



**ANDREW
LLOYD**

*Professor, Program Head,
Viral Immunology Systems
Program (VISP), The Kirby
Institute, UNSW Sydney*



**GAIL
MATTHEWS**

*Associate Professor, Viral
Hepatitis Clinical Research
Program, The Kirby
Institute, UNSW Sydney*



**KYLIE
VALENTINE**

*Associate Professor, Social
Policy Research Centre,
UNSW Sydney*



**KATHRYN
LEAFE**

*Executive Director, New
Zealand Needle Exchange
Programme, New Zealand*

Assessment and Management of Liver Fibrosis and Cirrhosis

Dr Jones & Partners is able to provide **Liver Elastography scans** (a non-invasive, ultrasound scan). This scan can help accurately assess patients with minimal fibrosis or with severe fibrosis/cirrhosis.

Several new medications have been made available on the PBS for the treatment of patients with Hepatitis C. These medications enable GPs to effectively treat and manage affected patients to minimise liver damage.

Elastography of the liver can be referred for both the initial assessment of disease (baseline) and monitoring of response to treatment (progression/response).

An Elastography Ultrasound scan is Medicare rebated. It can be referred by both GPs and Specialists.


Elastography is used for the initial assessment and ongoing management of patients with:

- Hepatitis B
- Hepatitis C
- Chronic liver disease
- Liver fibrosis
- History of heavy alcohol use/abuse
- Potential cirrhosis from non-alcoholic fatty liver disease.

The referring clinician should request “Liver Elasto” - one of the clinical indications above should be detailed on the referral form.

Patient Preparation - Standard preparation for an Upper Abdominal Ultrasound. Patients are required to fast for 6 hours prior to the exam.

Metavir Fibrosis Stages




Dr Jones & Partners is able to provide Elastography Ultrasound scans at many of our clinics located Centrally, North, South and Hills.

For bookings contact the nearest Dr Jones & Partners Medical Imaging Clinic.

For further information on Liver Elastography scans please contact the Radiologist at your nearest Dr Jones & Partners clinic or visit our website www.drjones.com.au

CONFERENCE APP



WI-FI DETAILS

Connect to: VIRALHEP18

Password: VIRALHEP18

The conference app is the best way to stay informed during the conference and it's free to download.

WHAT CAN I DO WITH THE APP?

- View the program by session or time, read the abstracts and let others know what you think about the session by sharing it on twitter
- Answer polling questions during presentations
- Search for speakers, read their bio and see what presentations they are giving
- View a list of all the sponsors and exhibitors and check where they're located
- Send a direct message to that person you have been trying to pin down for a meeting

HOW DO I GET THE APP?

The Conference App is available to download from the Apple app store or Google Play. Simply search for '**Events App by EventsAIR**'.


HOW DO I LOGIN TO THE APP?

Once you have found the app in your App Store:


1. Install the App.
2. The first time you open the app, you will need to **enter the event code: VH2018**
3. To login, enter your primary email address and pin (which you received in your app instructions email and final registration confirmation email).

VENUE FLOOR PLAN


GROUND FLOOR



LEVEL ONE



EXHIBITION FLOOR PLAN



EXHIBITION DIRECTORY



Booth number: 2

ADDRESSING SOME OF THE WORLD'S GREATEST HEALTH NEEDS

AbbVie is a biopharmaceutical company that has been in Australia for more than 75 years and is focused on developing new products and new ways to help people manage their health, and lead better lives. We tackle diseases where there is a significant need for better solutions and we come together every day to create, discover and deliver new ways to improve people's health and wellness in the areas of hepatitis C, immune-mediated conditions, neuroscience and oncology. Website link: www.abbvie.com.au.



ashm

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine

Booth number: 1

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) is a peak professional society representing a multidisciplinary health workforce –comprising membership of over 1500. ASHM manages accreditation programs for community prescribing of s100 medications; also providing education to health workers supporting HIV, hepatitis B and C patients.



Booth number: 4

Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases and cancer.



Booth number: 6



Booth number: 3

2018/19 will see new Fibroscan probe enhanced measuring and steatosis parameter upgrades to further improve accuracy, this will be available on recent models 430/530. If you have an older FS402, upgrading to FS430/530 processor is the best option with probes post 2012. Steatosis CAP is sometimes overlooked, it often influences stiffness. MTA is applying for a new MSAC rebate for HCV and HBV.



Booth number: 5

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.



Booth number: 8

Established for over 10 years, the Australasian Hepatology Association (AHA) is the peak professional body supporting and educating hepatology nurses and allied health professionals across Australia and New Zealand. Our membership consists of well-informed forward-thinking and experienced Hepatology professionals who encompass many specialist areas in a variety of settings. These include Hepatitis B and C treatment and care, chronic liver disease and chronic disease management, liver transplantation, liver cancer, health policy, sexual health, mental health, drug and alcohol, infectious diseases, indigenous health, culturally and linguistically diverse (CALD) health services, prison health services and nutrition.



Booth number: 7

Hepatitis Australia is the national peak community organisation to progress action on issues of importance to people affected by hepatitis B and hepatitis C. Our members are the eight state and territory hepatitis organisations. Our mission is to lead an effective national community response to hepatitis B and hepatitis C in Australia and realise our vision to see an end to hepatitis B and C in Australia. We work to improve health and social outcomes for all Australians who are at risk of or living with hepatitis B or C and pay particular attention to those groups which are at higher risk of infection or have a disproportionate burden of chronic disease.

Where will you be surprised?

Visit:
southaustralia.com/places-to-go


Adelaide
Convention Bureau



ADELAIDE
SOUTH AUSTRALIA


ADELAIDE
CONVENTION
CENTRE

MONDAY, 13 AUGUST 2018

7.30am	Registration Opens
8.30am - 11.00am	Opening Plenary 1 <i>Room: Hall M Chairs: Melanie Walker and Samuel Elliott</i>
8.35am - 8.40am	Welcome to Country <i>Aunty Georgina Williams, Kurna People</i>
8.40am - 8.45am	Committee Welcome <i>Dr Samuel Elliott, Principal General Practitioner, Riverside Family Medical Practice, SA, Australia</i>
8.45am - 8.50am	Government Welcome <i>The Honorable Stephen Wade, Minister for Health and Wellbeing, SA, Australia</i>
8.50am - 9.10am	No one left behind? The role of social policy in viral hepatitis <i>Kylie valentine, Deputy Director, Social Policy Research Centre, UNSW Art & Social Sciences, UNSW Sydney, NSW, Australia</i>
9.10am - 9.20am	Health Equity = Doing More for our Community <i>Kathryn Leafe, Executive Director, New Zealand Needle Exchange Programme (NEST), Christchurch, New Zealand</i>
9.20am - 9.30am	Lived experience speaker, Aboriginal and Torres Strait Islander Health <i>Anne Mitchell</i>
9.30am - 10.00am	Elimination of Hepatitis C in People Who Inject Drugs in Low and Middle Income Countries: The Final Frontier <i>Dr Sunil Solomon, Associate Professor of Medicine, John Hopkins University School of Medicine, USA</i>

MONDAY, 13 AUGUST 2018

10.00am - 10.30am	The Potential Impact of a Cure for Chronic Hepatitis B Infection: A Population Health and Economic Analysis in Australia <i>Dr Mehlika Toy, Research Scientist, Stanford University, USA</i>
10.30am - 10.40am	Australian Hepatitis Elimination Scorecard: Progress since the Australasian Viral Hepatitis Elimination Conference <i>Dr Joseph Doyle, Senior Lecturer, Monash University and Alfred Health; Deputy Director, Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia</i>
10.40am - 10.50am	National Strategies Australia <i>A representative from the Commonwealth Department of Health</i>
10.50am - 11.00am	New Zealand's Pathway to Elimination <i>Dr Alex Lampen-Smith, Gastroenterologist and Clinical Director, Hepatitis Foundation of New Zealand</i>
11.00am - 11.45am	Morning Tea and Poster Viewing <i>Room: Exhibition Hall L</i>
11.45am - 1.15pm	Cross Track Symposium 1 - Community Engagement <i>Room: Hall M Chairs: Margaret Hellard and Enaam Oudih</i>
11.45am - 11.57am	Deadly Liver Mob: Establishing New Services to Engage Aboriginal People who inject in Hepatitis C and STI Screening (#130) <i>Melinda Walker, Research Officer, Centre for Social Research in Health, UNSW Sydney and Kerrie-Anne Smith, Western Sydney Local Health District, NSW, Australia</i>
11.57am - 12.09pm	Beyond Information - Hepatitis B Engagement with the Chinese Community in Adelaide (#35) <i>Cecilia Lim, Coordinator Information Resources, Hepatitis SA, SA, Australia and Margery Milner, Viral Hepatitis Nurse, The Queen Elizabeth Hospital, Adelaide, SA, Australia</i>

MONDAY, 13 AUGUST 2018

12.09pm - 12.21pm	Too soon for back-slapping and counting chickens: Engagement with sub-populations of people who use drugs <i>Melanie Walker, Chief Executive Officer, Australian Injecting & Illicit Drug Users League (AIVL), Canberra, ACT, Australia</i>
12.21pm - 12.33pm	Barriers and Facilitators for Ensuring Equitable Access to DAAs: A Clinical Perspective <i>Dr Philip Read, Director, Kirkeaton Road Centre, NSW, Australia</i>
12.33pm - 12.45pm	Collaborative Partnerships are Needed to Eliminate Hepatitis C in Marginalised Populations <i>Janice Pritchard-Jones, Hepatitis Coordinator, Sydney Local Health District, Sydney, NSW, Australia</i>
12.45pm - 12.55pm	Q&A
12.55pm - 1.15pm	Panel Discussion <i>Facilitators: Margaret Hellard, Enaam Oudh. Panellists: Chen Bin, Syl Phillips-Ayre, Catherine Kostovski, Stone Crawford, Jude Byrne, Jack Wallace and Deborah Warneke-Arnold</i>
1.15pm - 2.15pm	Lunch and Poster Viewing <i>Room: Exhibition Hall L</i>
1.15pm - 2.15pm	Early Career Networking Event <i>Room: L3 Sunil Solomon, Margaret Hellard, Andrew Lloyd, Michael Ninburg, and Katherine McQuillan</i>
1.35pm - 2.05pm	Poster Tour - Community & Social Research Theme. <i>Room: Exhibition Hall Facilitator: kylie valentine</i>
1.35pm - 1.40pm	#2 – Look After Your Blood – Developing a Blood-Borne Virus Social Marketing Campaign for Young Aboriginal People (#71 <i>Judith Bevan</i>

MONDAY, 13 AUGUST 2018

1.40pm - 1.45pm	#3 – Reorientation of Hepatitis C Services in Victoria (#51) <i>Elizabeth Birbills</i>
1.45pm - 1.50pm	#5 – Community Conversations with People Who Inject Drugs in Southern Sydney (#62) <i>Tracey Brown</i>
1.50pm - 1.55pm	#6 – Peer Insights: Understanding Motivators and Barriers to the Uptake of Hepatitis C Treatments among People Who Inject Drugs (#21) <i>Susan Chong</i>
1.55pm - 2.00pm	#14 – Barriers and Help-Seeking Practices: Perspectives of South Sudanese People with Chronic Hepatitis B in Australia (#123) <i>William Mude</i>
2.00pm - 2.05pm	#15 – GUD WUN POR PLES Communities Creating for Community: A Sustainable Resource Project (#330) <i>Samantha White</i>
2.15pm - 3.45pm	Plenary 2 – Plenary proffered paper abstract session <i>Room: Hall M Chairs: Scott Bowden and Vanessa Towell</i>
2.15pm - 2.30pm	Big Mob, Big Job – Hepatitis B Sero-Coding The Top End (#118) <i>Kelly Hosking, Continuous Quality Improvement Facilitator, Top End Health Service, Northern Territory Government, NT, Australia</i>
2.30pm - 2.45pm	Hepatitis B Community Partnerships – Dancing with Cinderella (#70) <i>Kathryn Stewart, Program Manager – Hepatitis B, Hepatitis Australia, ACT, Australia</i>
2.45pm - 3.00pm	Evaluation of The Xpert® HCV Fingertstick Viral Load Point-of-Care-Assay (#65) <i>Dr Tanya Applegate, Senior Lecturer, The Kirby Institute, UNSW Sydney, NSW, Australia</i>

MONDAY, 13 AUGUST 2018

3.00pm - 3.15pm	Hepatitis C Virus Infection among People Who Inject Drugs In Australia: Monitoring Exposure, Treatment Uptake and Viraemic Prevalence (#98) <i>Dr Jenny Iversen, Senior Lecturer, The Kirby Institute, UNSW Sydney, NSW, Australia</i>			
3.15pm - 3.30pm	Adherence to Sofosbuvir and Velpatasvir among People With Chronic HCV Infection and Recent Injection Drug Use: The Simplify Study (#83) <i>Evan Cunningham, Postdoctoral Fellow, The Kirby Institute, UNSW Sydney, NSW, Australia</i>			
3.30pm - 3.45pm	The Matter of Reinfection: Attitudes among Australian Prisoners from the SToP-C Study (#37) <i>Jake Rance, Research Fellow, Centre for Social Research in Health, UNSW Sydney, NSW, Australia</i>			
3.45pm - 4.15pm	Afternoon Tea and Poster Viewing <i>Room: Exhibition Hall L</i>			
4.15pm - 5.45pm	Symposium - Measuring Progress Towards Viral Hepatitis Elimination Goals - Data for Action <i>Room: Hall M Chairs: Mark Stooove and Richard Gray</i>	4.15pm - 5.45pm Proffered Papers - Innovations in Hepatitis B <i>Room: City Room 1 Chairs: Jack Wallace and Susan Hay</i>	4.15pm - 5.50pm Proffered Papers - Testing, Treating and Cancer Screening <i>Room: City Room 2 Chairs: Scott Bowden and Margery Milner</i>	Management of Viral Hepatitis in Lower Middle Income Countries - Making the best of what we have <i>Dr Sunil Solomon, Associate Professor of Medicine, John Hopkins University School of Medicine, USA</i>
4.15pm - 4.30pm	Strategies, Targets and Indicators. How Will We Measure our Progress Towards Hepatitis B and Hepatitis C Elimination <i>Professor Margaret Hellard, Deputy Director, Burnet Institute, VIC, Australia</i>	4.15pm - 4.30pm No Dramas: Eliminating Hepatitis B - Related Shame In The Chinese Community (#326) <i>Win Yee Tan</i>	4.15pm - 4.30pm	

MONDAY, 13 AUGUST 2018

4.30pm - 4.45pm	HBV and HCV Elimination Targets: Which are feasible? <i>Professor Gregory Dore, Head Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, NSW, Australia</i>	4.30pm - 4.45pm	Peer Support Service for Culturally and Linguistically Diverse (CALD) People Living With Hepatitis B - The Efforts, The Risks and the Benefits (#80) <i>Enaam Oudih</i>	4.30pm - 4.45pm	Australian consensus statement on hepatitis B management during immunosuppression for haematological and solid-organ malignancies (#332) <i>Joseph Doyle</i>
4.45pm - 5.00pm	The Role of Geo-mapping of Viral Hepatitis in Monitoring Care Cascade and Driving Local Responses <i>Benjamin Cowie, Epidemiologist, The Doherty Institute, VIC, Australia</i>	4.45pm - 5.00pm	Overcoming Language and Cultural Barriers – Engaging Non-English Speaking Communities for Education (#102) <i>Zhihong Gu</i>	4.45pm - 5.00pm	Predicting Risk of Hepatocellular Carcinoma for Patients with Chronic Hepatitis B Using Serum Levels of Spliced Hepatitis B Virus DNA (#49) <i>Peter Revill</i>
5.00pm - 5.15pm	Population-level impact of DAA treatment programs <i>Maryam Alavi, Lecturer, The Kirby Institute, UNSW Sydney, NSW, Australia</i>	5.00pm - 5.15pm	HEP B 1, 2, 3: Hepatitis B Community Mobilisation and Immunisation (#26) <i>Meg Perrier</i>	5.00pm - 5.15pm	Investigating the Use of a Urinary Metabolite Panel as a Screening Test for Diagnosis of Hepatocellular Carcinoma in a Remote Aboriginal Setting (#125) <i>Jack Wang and Kevin Muller</i>
5.15pm - 5.45pm	Facilitator: Mark Stoove Panel: Richard Gray, Margaret Hellard, Greg Dore, Benjamin Cowie, Maryam Alavi, Tim Duck and Phillip Read	5.15pm - 5.30pm	Hip Hop As A Narrative Tool for Hepatitis B and Liver Cancer Prevention (#74) <i>Nafisa Yussf</i>	5.15pm - 5.30pm	Synthesis of Hbeag-Specific Epitope-Cloned HBV Bio- Nanoparticles (#48) <i>Yianni Droungas</i>

MONDAY, 13 AUGUST 2018

	5.30pm - 5.35pm	Do Broad Population Health Promotion Campaigns Reach CALD Communities? (#34) <i>Natali Smud</i>	5.30pm - 5.35pm	Evaluation Of A Hepatitis C Virus Core Antigen Assay In Dried-Blood Spots: A Cohort Study (#75) <i>Tanya Applegate</i>
	5.35pm - 5.40pm	"Watch, Talk, Share" - A Community Approach in Developing Viral Hepatitis Video for the Vietnamese Community (#104) <i>Zhihong Gu and Triet Minh Ho (Steven)</i>	5.35pm - 5.40pm	Capacity of Non-Invasive Hepatic Fibrosis Algorithms to Replace Transient Elastography to Exclude Cirrhosis in People with Hepatitis C Virus Infection: A Multi-Centre Observational Study (#3) <i>Melissa Kelly</i>
	5.40pm - 5.45pm	Q&A	5.40pm - 5.45pm	Evaluation of the Hologic Aptima HCV Quant Diagnostic Assay for Detection of HCV RNA from Dried Blood Spots (#63) <i>Beth Catlett</i>
			5.45pm - 5.50pm	An Immunochromatographic Test for Measurement of Alanine Aminotransferase (ALT) at Point-of-Care (#91) <i>David Anderson</i>
5.45pm - 7.00pm	Welcome Reception and Poster Viewing, including CSRH and NDRI: Health Promotion Prize Announcement <i>Room: Exhibition Hall</i>			

TUESDAY, 14 AUGUST 2018

7.00am	Registration opens
8.45am - 11.00am	Plenary 3 <i>Room: Hall M Chairs: Vanessa Towell and Helen Tyrrell</i>
8.45am - 9.00am	Hepatitis C Lived experience speaker <i>Solomon Woreta</i>
9.00am - 9.05am	"B-Side" Project- Increasing Awareness of Hepatitis B By Music, Multimedia Story Board and Social Media Campaign (#137) <i>Suresh Sharma, Nurse Practitioner, John Hunter Hospital - Department of Gastroenterology, Newcastle, NSW, Australia</i>
9.05am - 9.15am	Annual Report on the Hepatitis Cascades of Care, Trends and Behaviour - The Kirby Institute, UNSW Sydney and Centre for Social Research in Health, UNSW Sydney <i>Greg Dore and Carla Treloar</i>
9.15am - 9.45am	Management of Chronic Hepatitis B: Challenging Therapeutic Paradigms? <i>Associate Professor Gail Matthews, Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney, NSW, Australia</i>
9.45am - 10.15am	Viral Hepatitis, Harm Reduction and Whole Person Health: the Role of Community-based Organizations <i>Michael Ninburg, President, The World Hepatitis Alliance; Executive Director, The Hepatitis Education Project, USA</i>
10.15am - 10.45am	Lessons from the inside: Enhancing hepatitis B and C prevention and treatment in the prison sector <i>Professor Andrew Lloyd, Infectious Diseases Physician and Immunovirology Researcher, The Kirby Institute, UNSW Sydney, NSW, Australia</i>
10.45am - 11.00am	The Levinia Crooks Emerging Leader Award Presentation: Measuring disparities in progress toward elimination: Using data for action <i>Award award presented by Vanessa Towell, National Policy and Education Division Manager, The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, NSW, Australia.</i>

TUESDAY, 14 AUGUST 2018

11.00am - 11.30am	Morning Tea and Poster Viewing <i>Room: Exhibition Hall L</i>
11.30am - 1.00pm	Cross Track Symposium 2 - Viral Hepatitis in Correctional Settings <i>Room: Hall M Chairs: Andrew Lloyd and Mark Stooove</i>
11.30am - 11.40am	The role of Corrective Services and Justice Health staff in Promoting HCV Treatment Uptake among the Prisoner Population in NSW Correctional Centres <i>Professor Carla Treloar, Director, Centre for Social Research in Health, UNSW Sydney, NSW, Australia</i>
11.40am - 11.50am	HealthELink, Online Model of HCV Treatment within South Australian Prisons <i>Dr Edmund Tse, Head of Hepatology and Staff Specialist, Royal Adelaide Hospital, SA, Australia</i>
11.50am - 12.00pm	HCV Transmission and Risk Behaviour in NSW Prisons <i>Dr Behzad Hajari, Lecturer, The Kirby Institute, UNSW Sydney, NSW, Australia</i>
12.00pm - 12.10pm	Nurse-led model of HCV care and treatment in VIC prisons <i>Anne Craigie, Hepatitis Clinical Nurse Consultant, St Vincent's Hospital Melbourne, VIC, Australia</i>
12.10pm - 12.20pm	HBV Prevalence, Prevention and Treatment in NT Prisons <i>Dr Jane Davies, Infectious Diseases Specialist, Menzies School of Health Research, NT, Australia</i>
12.20pm - 13.00pm	<i>Facilitator: Andrew Lloyd. Panellist: Mark Stooove, Carla Treloar, Edmund Tse, Behzad Hajari, Jane Davies, Anne Craigie, Michael Ninburg, Shannon Wright and Michael Levy</i>
1.00pm - 2.00pm	Lunch and Poster Viewing <i>Room: Exhibition Hall L</i>

TUESDAY, 14 AUGUST 2018

1.00pm - 2.00pm	Modelling Workshop <i>Room: L3</i>
1.05pm - 1.20pm	Introduction - What are models and what purpose do they serve? <i>Dr Karen McCulloch, Research Fellow, The Doherty Institute, Melbourne, VIC, Australia</i>
1.20pm - 1.30pm	Modelling for Hepatitis C <i>Dr Nick Scott, Econometrician, Burnet Institute, VIC, Australia</i>
1.30pm - 1.40pm	Modelling for Hepatitis B <i>Dr Karen McCulloch, Research Fellow, The Doherty Institute, Melbourne, VIC, Australia</i>
1.40pm - 2.00pm	Q&A Discussion with Panel <i>Mehlika Toy, Nick Scott, Karen McCulloch and Richard Gray</i>
1.20pm - 1.50pm	Poster Tour - Public Health and Clinical Care <i>Room: Exhibition Hall Facilitator: Alisa Pedrana.</i>
1.20pm - 1.25pm	#36 – Epidemiologic Trends in Viral Hepatitis Notifications in Australia, 1996-2016 (#140) <i>Laura Thomas</i>
1.25pm - 1.30pm	#37 – Hepatitis B Status Is Significantly Associated With Sexually Transmissible Infection Positivity – A Case Controlled Study At A Publicly Funded Sexual Health Service In Sydney, Australia (#143) <i>Rick Varma</i>

TUESDAY, 14 AUGUST 2018

1.30pm - 1.35pm	#44 – Outcomes Of Community-Based Hepatitis C Treatment Using An Ehealth Model Of Care (#58) <i>James Haridy</i>			
1.35pm - 1.40pm	#45 – Nurses Role when the Hepatitis C is Cured But the Cirrhosis Remains (#329) <i>Janice Pritchard-Jones</i>			
2.00pm - 3.30pm	Symposium - Simplifying diagnosis and treatment for hepatitis B & C – now and into the future <i>Room: Hall M Chairs: Gail Matthews and Melanie Eagle</i>	2.00pm - 3.30pm	Proffered Papers - Responding to Challenges in Hepatitis C Care and Treatment <i>Room: City Room 1 Chairs: kylie valentine and Tom Rees</i>	2.00pm - 3.30pm
2.00pm - 2.15pm	Simplification and Implementation of Existing Diagnosis Tools – How Can we Use What we Have? <i>Dr Tanya Applegate, Senior Lecturer, The Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Sydney NSW, Australia</i>	2.00pm - 2.15pm	Hear Ye! Hear Ye! Getting Out The Good News on Hep C Cure (#73) <i>Grace Crowley</i>	Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up (#77) <i>(Jisoo) Amy Kwon</i>

TUESDAY, 14 AUGUST 2018

2.15pm - 2.30pm	The Development of New Simplified Diagnostic Technologies to Reach those in Need – Our Challenges for the Next 5 Years <i>Associate Professor David Anderson, Deputy Director, The Burnet Institute, Melbourne, VIC, Australia</i>	2.15pm - 2.30pm	The National Stigma Indicator Project: Key Findings And Lessons Regarding People Living With HCV And People Who Inject Drugs (#23) <i>Timothy Broady</i>	2.15pm - 2.30pm	Mapping Progress Towards Australia's National Hepatitis C Strategy Targets (#327) <i>Jennifer MacLachlan</i>
2.30pm - 2.45pm	Clinical Challenges for the Simplification of HCV Treatment - Optimising the Care Cascade <i>Dr Amanda Wade, ID Physician, Head Hepatitis Clinic Geelong Hospital and EC West, VIC, Australia</i>	2.30pm - 2.45pm	Reasons For Not Seeking HCV Treatment Among A Sample Of People Who Inject Drugs (#60) <i>Leith Morris</i>	2.30pm - 2.45pm	Progress Towards Hepatitis Elimination in Mongolia: Initial Outcomes of the Healthy Liver National Program 2017-2020 (#56) <i>Narantuya Jadamba</i>
2.45pm - 3.00pm	Simplification of HBV Treatment to Reach Everyone - What Tools do we Need to Engage Aboriginal & Torres Strait Islander and CALD Communities? <i>Dr Jane Davies, Infectious Diseases Specialist, Menzies School of Health Research, NT, Australia</i>	2.45pm - 3.00pm	"I Love Not Being Infectious...": Perceptions Of Hepatitis C Cure Post DAA Treatment (#6) <i>Jacqui Richmond</i>	2.45pm - 3.00pm	Recurrent Viraemia Following Successful HCV DAA Therapy among People with Recent Injecting Drug Use: The Simplify and D3feat Studies (#142) <i>Evan Cunningham</i>

TUESDAY, 14 AUGUST 2018

3.00pm - 3.30pm	Panel Discussion <i>Facilitator: Gail Matthews.</i> <i>Panellists: Melanie Eagle, Tanya Applegate, David Anderson, Amanda Wade, Jane Davies, Sinead Shells and Susan Hay</i>	3.00pm - 3.15pm	Staying Honest About HCV Treatment Access – Barriers to Treatment from a QulHN Perspective (#113) <i>Tegan Nuckey</i>	3.00pm - 3.05pm	Accessing Hepatitis C Treatment in New South Wales: Where are People who Inject Drugs Being Treated? (#114) <i>Louise Geddes</i>
3.15pm - 3.20pm		3.15pm - 3.20pm	The Kombi Clinic – It's The End of The Road for Hep C! (#24) <i>Matthew Young</i>	3.05pm - 3.20pm	High Efficacy of Direct-Acting Antiviral Therapies for Hepatitis C Following Universal Access in Australia: The REACH-C Cohort (#134) <i>Jasmine Yee</i>
3.20pm - 3.25pm		3.20pm - 3.25pm	Stigma Stories: Speaking Up To Stop The Silent Killer (#13) <i>Jack Gunn</i>	3.20pm - 3.25pm	Universal Access to DAA Therapy Paves the Way for HCV Control and Elimination among People Living with HIV in Australia (#28) <i>Marianne Martinello</i>
3.25pm - 3.30pm		3.25pm - 3.30pm	Q&A	3.25pm - 3.30pm	Reviewing Harm Reduction Strategies in NSW Prisons: A Collaborative Approach to Reduce Transmission of Blood Borne Viruses and Sexually Transmissible Infections (#86) <i>Tom Wright</i>

TUESDAY, 14 AUGUST 2018

3.30pm - 4.00pm	Afternoon Tea and Poster Viewing <i>Room: Exhibition Hall L</i>			
4.00pm - 5.30pm	Symposium - A Community Lens on the Viral Hepatitis Cascade of Care <i>Room: Hall M Chairs: Michael Ninburg and Lynnaire Matthews</i>	4.00pm - 5.30pm	Proffered Papers - Care and Treatment among key populations <i>Room: City Room 1 Chairs: Edmund Tse and Suzanne Sheppard-Law</i>	4.00pm - 5.30pm Proffered Papers - Prioritising Hepatitis B - Epidemiology and Program Need <i>Room: City Room 2 Chairs: Nicole Allard and Yvonne Drazic</i>
4.00pm - 4.05pm	An introduction to the cascade of care <i>Professor Carla Treloar, Director, Centre for Social Research in Health, UNSW Sydney, NSW, Australia</i>	4.00pm - 4.15pm	Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior following Elbasvir (Ebr)/Grazoprevir (Gzr) Treatment in Participants on Oplate Agonist Therapy (OAT): Co-Star Part B (#59) <i>Gregory Dore</i>	Investigating Trends in Hepatitis B Epidemiology within Indigenous Populations in the Northern Territory (#124) <i>Ashleigh Qama</i>
4.05pm - 4.20pm	Who and What is missing from the hepatitis C treatment Cascade of Care? <i>Sione Crawford, Chief Executive Officer, Harm Reduction Victoria, Australia</i>	4.15pm - 4.30pm	Daily Dosing of Direct Acting Antivirals (DAAs) from a Public Opioid Substitution Treatment (OST) Program for Marginalised Clients in Kings Cross, Sydney (#44) <i>Phillip Read</i>	Modelling Hepatitis B In Australia: Improved Estimates of the Burden of Disease (#122) <i>Karen McCulloch</i>

TUESDAY, 14 AUGUST 2018

4.20pm - 4.35pm	Hepatitis B and the cascade of care: Testing vs screening vs diagnosis vs chronic infection vs infectious vs liver disease <i>Dr Jack Wallace, Senior Research Officer, Burnet Institute, VIC, Australia and Nafisa Yussf, Community Engagement Officer, Cancer Council Victoria, Australia</i>	4.30pm - 4.45pm	Prevalence of NS5a Resistance Associated Substitutions and HCV DAA Treatment Outcomes among People Living With HIV in Australia (#127) <i>Tanya Applegate</i>	4.30pm - 4.45pm	Hepatitis B Treatment in Australia – What's The Magic Number? (#129) <i>Nicole Romero</i>
4.35pm - 4.50pm	Using Liver Cancer Prevention Messages to Scale Up Diagnosis of People with Hepatitis B (#67) <i>Emily Adamson, Policy and Program Advisor, Cancer Council Victoria, Australia</i>	4.45pm - 5.00pm	Phylogenetic Clustering Patterns among People Living with HIV and Hepatitis C in Australia (#128) <i>Tanya Applegate</i>	4.45pm - 5.00pm	Morbidity and Mortality associated with Viral Hepatitis in Victoria (#138) <i>Chelsea Brown</i>
4.50pm - 5.30pm	Panel members: Michael Ninburg, Lynnaire Matthews, Sione Crawford, Jack Wallace, Jillian White, Nafisa Yussf, and Rosalie Altus	5.00pm - 5.05pm	High Efficacy of 8 Weeks Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir among People with Recent Genotype 1 HCV Infection (#29) <i>Marianne Martinello</i>	5.00pm - 5.15pm	Cultural and Linguistic Diversity of People Living with Chronic Hepatitis B, 2011–2016: Changing Migration, Shifting Epidemiology (#121) <i>Jennifer MacLachlan</i>
		5.05pm - 5.10pm	Clinicians Attitudes Towards the Treatment of Patients with Hepatitis C who are Injecting Drug Users (CATHPIN) (#99) <i>Mary Fenech</i>	5.15pm - 5.20pm	Disease Eradication – The Journey Through Big Data (#46) <i>Greg Royal</i>

TUESDAY, 14 AUGUST 2018

	5.10pm - 5.15pm	TEST AND TREAT! – A Community Based Viral Hepatitis Screening and Treatment Service in a Sydney Based Needle and Syringe Program (NSP) (#72) <i>Virginia McMahon and Lisa Dowdell</i>	5.20pm - 5.25pm	Hepatitis B and Immigration in Australia (#89) <i>Zindia Narver</i>
	5.15pm - 5.20pm	Utilising A Social Network Nurse –Led Model To Engage People Who Inject Drugs in the Community into HCV Treatment and Care (#93) <i>Joseph Doyle</i>	5.25pm - 5.30pm	Q&A
	5.20pm - 5.30pm	Q&A		
7.00pm	Conference Dinner <i>National Wine Centre</i>			

WEDNESDAY, 15 AUGUST 2018

8.00am	Registration opens			
8.30am - 10.00am	Proffered Papers - Taking Hepatitis C Care to the Community and Beyond <i>Room: Hall M Chairs: Carla Gorton and Rosalie Altus</i>	8.30am - 10.00am	Proffered Papers - Specialised work with identified communities <i>Room: City Room 1 Chairs: Melanie Walker and Alex Lampen-Smith</i>	8.30am - 10.00am Proffered Papers - Sharing innovations in Clinical Care <i>Room: City Room 2 Chairs: Samuel Elliott and Rose Magdalene</i>
8.30am - 8.45am	Effectiveness and Acceptance of an Intensive Screening and Case Finding Intervention in a Public OTP Clinic (#328) <i>Janice Pritchard-Jones</i>	8.30am - 8.45am	A Thoughtful and Collaborative Approach to Hepatitis B is Essential when Working in Remote Aboriginal Communities (#117) <i>Paula Binks</i>	Real-World Outcomes of Direct-Acting Antiviral Therapy for Chronic Hepatitis C Following Unrestricted Access in Australia: The South Australian Experience (#57) <i>James Haridy</i>
8.45am - 9.00am	An Unmet Need for Hepatitis C Testing at Needle and Syringe Services - Lessons Learned from the Rapid-EC Feasibility Study (#100) <i>Alisa Pedrana</i>	8.45am - 9.00am	Partnering Hepatology Nurses and Peer Workers to Increase Treatment among Marginalised People (#87) <i>Kyle Leadbeater</i>	Hepatitis C Work-Up And Treatment: Innovation In Correctional Nursing Practice (#9) <i>Susan O'Neill</i>
9.00am - 9.15am	The Covert C: Prevalence, Risk Factors and Management of Hepatitis C Infection among Psychiatric In-Patients (#36) <i>Jeyamani Ramachandran</i>	9.00am - 9.15am	Supporting Prisoners Living with a Blood Borne Virus (#4) <i>Emma Williams</i>	Never Fear Pencat Is Here - A Nationally Available Tool For Chronic Hepatitis B Management In General Practice (#61) <i>Lisa Dowdell</i>

WEDNESDAY, 15 AUGUST 2018

9.15am - 9.30am	Elimination of Hepatitis C in NSW Prisons: Possible or Pointless? The Experience of Justice Health & Forensic Mental Health Network Two Years After the Introduction of New Curative Treatments (#79) <i>Colette McGrath</i>	9.15am - 9.30am	The Social Benefits of Successful DAA Therapy Beyond Cure: A Structural Competency Approach (#97) <i>Carla Trebar</i>	9.15am - 9.30am	Adherence and Virological Outcomes for Hepatitis B Antiviral Therapy amongst Indigenous Australians in the Remote Top End, Northern Territory (#144) <i>Caroline Lee</i>
9.30am - 9.35am	Hepatitis C In The ED - Screening For Hepatitis C Infection in the Hospital Emergency Department using Point-Of-Care Testing (#92) <i>Alex Thompson</i>	9.30am - 9.35am	Art Inside: Engaging Prisoners In Viral Hepatitis (#33) <i>Steven Taylor</i>	9.30am - 9.35am	Recall Can Increase Treatment Uptake: An Audit of Positive Hepatitis C PCR Tests at the Kirketon Road Centre (#42) <i>Rebecca Lothian</i>
9.35am - 9.40am	Hepatitis C Virus (HCV) Testing, Liver Disease Assessment and Direct-Acting Antiviral (DAA) Treatment Uptake and Outcomes in a Homeless Service in Sydney: The Liverlife Study (#10) <i>Sahar Bajis</i>	9.35am - 9.40am	Exploring The Acceptability Of Point-Of-Care Hepatitis C Testing For People Who Inject Drugs: A Qualitative Analysis (#107) <i>Alisa Pedrana</i>	9.35am - 9.40am	Quiet Achievers – A Multi- Disciplinary Approach to HCV Treatment and Management in Marginalised Populations – The QuHN Outreach Model (#96) <i>Mary Fenech</i>
9.40am - 9.45am	Point of Care Rapid HCV Antibody Testing of Needle Exchange Clients: Results from a New Zealand Pilot Study (#7) <i>Geoff Noller</i>	9.40am - 9.45am	LiverBetterLife: Hepatitis C Treatment Awareness Campaign in Rural South Australia (#66) <i>Nicole Taylor</i>	9.40am - 9.45am	Implementation of a Hospital- Led, Community Based, Hepatology Nurse Practitioner Model of Care in an Inner-City Sydney Setting (#132) <i>Sinead Shells</i>

WEDNESDAY, 15 AUGUST 2018

9.45am - 9.50am	When Hep C Care & Treatment Meets NSP... Its Positively Hep (#40) <i>Julie Page</i>	9.45am - 9.50am	Far North Queensland Liver Health Champions (#85) <i>Morgan Dempsey</i>	9.45am - 10.00am	Q&A
9.50am - 10.00am	Q&A	9.50am - 9.55am	QulHN Townsville TMP: A Flexible Approach to Offering Hepatitis C Treatment (#112) <i>Julie-ann Markham</i>		
		9.55am - 10.00am	Increasing Hepatitis C Testing and Treatment among Sexually Adventurous Men Who Have Sex with Men (#1) <i>Loren Brener</i>		
10.00am - 10.30am	Morning Tea <i>Room: Exhibition Hall L</i>				
10.30am - 12.00pm	Closing Plenary - Be Informed <i>Room: Hall M Chairs: Carla Treloar and Benjamin Cowie</i>				
10.30am - 10.40am	Hepatitis B Lived experience speaker				
10.40am - 10.50am	No One Left Behind: The Case for Strengthening Health Information Management Systems <i>Michael Larkin, Blood Borne Virus Program Coordinator, Aboriginal Health Council of South Australia, SA, Australia</i>				

WEDNESDAY, 15 AUGUST 2018

10.50am - 11.50am	Panel Discussion - You CAN ask that <i>Facilitators: Carla Treloar and Benjamin Cowie</i> <i>Clinical and Health Worker Panel: Dr Victoria Cock, Dr Jill Benson, Dr Alex Lampen-Smith, Michael Larkin and Mary Fenech</i> <i>People with Lived Experience Panel: Nafisa Yussf, Yvonne Drazic, Lisa Carter, Carol Holly, Sione Crawford</i>
11.50am - 12.00pm	Conference Closing remarks <i>Alexis Apostolellis, Chief Executive Officer, The Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, NSW, Australia</i>
12.00pm	Conference close

POSTER LISTING

Poster	Title	First Name	Last Name
COMMUNITY & SOCIAL RESEARCH			
1	Hepatitis C - Reaching The High Hanging Fruit: The Test Cure Live Initiative	Wendy	Anderson
2	Look After Your Blood – Developing A Blood-Borne Virus Social Marketing Campaign For Young Aboriginal People	Judith	Bevan
3	Reorientation Of Hepatitis C Services In Victoria	Elizabeth	Birbilis
4	A Community Based Model Of Care For Migrants And Refugees With Viral Hepatitis, At The Ethnic Communities Council Of Queensland (ECCQ).	Marrianne	Black
5	Community Conversations With People Who Inject Drugs In Southern Sydney	Tracey	Brown
6	Peer Insights: Understanding Motivators And Barriers To The Uptake Of Hepatitis C Treatments Among People Who Inject Drugs	Susan	Chong
7	Removing Barriers To Testing For People: Pre-Paid, Flexible And Hasle Free	Timothy	Duck
8	Blood-Borne Virus Prevention And Blood Awareness Among Men Who Inject Performance And Image Enhancing Drugs	Renaë	Fomiatti
9	Short And Simple Messages Are Not Enough – Developing A Resource For People Living With Chronic Hepatitis B From Non-English Speaking Backgrounds	Zhihong	Gu
10	Reaching Out To The Chinese Community	Zhihong	Gu
11	Working Together The 'Korean Health Expo' Increases Awareness Of Hepatitis B And General Health Issues And Services Amongst The Korean Community	Mina	Kim
12	Qualitative Needs Assessment Investigating The Information And Support Needs Of People With Hepatitis B And Hepatitis C In The ACT	Kerrie	Mckenzie
13	Increasing Capacity To Work Effectively With Young People At Risk Of Hepatitis C	Virginia	McMahon

Poster	Title	First Name	Last Name
14	Barriers And Help-Seeking Practices: Perspectives Of South Sudanese People With Chronic Hepatitis B In Australia	William	Mude
15	GUD WUN POR PLES Communities Creating for Community: A Sustainable Resource Project	Samantha	White
16	How Do We Reach The Other 75% Of People With Untreated Chronic Hepatitis C?	Leanne	Myers
17	Barriers to Eradicating Hep C	Joss	O'Loan
18	Hepatitis B Needs Assessment For Afghani Community In South Australia	Enaam	Oudih
19	"Hep B: Could It Be Me? An Inclusive Communications Strategy Promoting Testing For Hepatitis B Testing In Diverse Communities	Sonam	Paljor
20	LiverWELL: An Interactive Mobile App for Liver Health Management	Mark	Pearce
21	"We Belong" - A Peer Based Review On Extension, Inclusion And Appropriateness Of Health Care In The Multicultural Communities.	Anup	Pereira
22	Mobilisation Of CALD Communities Around Sensitive Issues	Wael	Sabri
23	HEPready: An Innovative Model For Viral Hepatitis Workforce Development	Kate	Webster
24	The Narrowest Point: Hepatitis C in Remand	Mary	O'Flynn
EPIDEMIOLOGY, PUBLIC HEALTH & PREVENTION			
25	Hepatitis D: Epidemiology In South Australia 2005-2014	Anushia	Ashokan
26	Seroprevalence And Risk Factors Of Hepatitis E Among Population Aged 15- 49 Years: A Cross Sectional Study In Regional Locality, Sudan	Hiba WITHDRAWN	Azrag WITHDRAWN
27	Initiations Of New Direct Acting Antiviral (DAA) Treatment For Chronic Hepatitis C (HCV) In Western Australia (WA): A Review Of The First Year	Jude	Bevan

Poster	Title	First Name	Last Name
28	Hepatitis B – A Systems Approach To Reduce Hepatitis B Infections In NSW	Timothy	Duck
29	Hepatitis C Elimination In Nsw By 2028 - Priming The System To Deliver Equity In NSW	Timothy	Duck
30	Implementation Of An Online Workforce Development Program For Community Pharmacists	Nicole	Gunn
31	Evaluation of the Impact of Hepatitis B s100 Community Prescribing in Australia	Katelin	Haynes
32	Hepatitis C Knowledge, Readiness For Treatment, Subsequent Patient Experience And Side Effects Of Direct Acting Antivirals (DAA) In Clients Attending A Drug And Alcohol Clinic.	Xiu Qin	Lim
33	Barriers And Facilitators To Diagnosis And Treatment Commencement And Completion Among First Nations People Living With Hepatitis C Virus (HCV)	Emily	Phillips
34	Elements Of Community-Based Models Of Care For Treating Hepatitis C	Davoud	Pourmarzi
35	Monitoring The Elimination Of Mother-To-Child Transmission Of Hepatitis B In Australia	Nicole	Romero
36	Epidemiologic Trends In Viral Hepatitis Notifications In Australia, 1996-2016	Laura	Thomas
37	Hepatitis B Status Is Significantly Associated With Sexually Transmissible Infection Positivity – A Case Controlled Study At A Publicly Funded Sexual Health Service In Sydney, Australia	Rick	Varma
38	Evaluation Of An Integrated Nurse Model Of Care Providing Hepatitis C Treatment To People Attending Homeless Services In Melbourne, Australia	Bradley	Whitton

SCIENCE AND CLINICAL CARE


39	Viral Hepatitis - A Paediatric Experience	Brooke	Andersen
40	Analysis Of The Lipidome In Chronic Hepatitis C Virus (HCV) Shows Genotypic Differences Which Resolve With Viral Clearance	Margaret	Bassendine
41	Towards Elimination - Increasing Access and Expediting Hepatitis C Treatment in a Rural Correctional Facility	Melany	Day


Poster	Title	First Name	Last Name
42	Impact Of Acid-Reducing Agents On Effectiveness Of Elbasvir/Grazoprevir In Treating Us Veterans Affairs Population With Hepatitis C Virus	Adrian	Desfontaines
43	Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1–6 and Recent Drug Use.	Gregory	Dore
44	Outcomes Of Community-Based Hepatitis C Treatment Using An Ehealth Model Of Care	James	Haridy
45	Nurses role when the Hepatitis C is cured but the Cirrhosis remains	Janice	Pritchard-Jones
46	The Prevalence of Serum Hepatitis B Surface Antibody (HBVsAb) < 10 IU/L in Hepatitis C PCR Positive Patients in Two Large Specialist General Practices in South East Queensland (Bris/Gold Coast).	Gary	Keogh
47	Effectiveness And Utilization Of Elbasvir/Grazoprevir In Hcv Genotype 1 And 4 Infection In The Veteran Affairs Healthcare System In The United States	Susila	Kulasingam
48	Deep Sequencing Analysis Of Hbv Isolated From Patient Samples During A Treatment Cessation Trial.	Margaret	Littlejohn
49	Difficult Venous Access: Addressing This Barrier To Care In Hepatitis Treatment Clinics	Susan	Mason
50	Engaging Hard To Reach Populations With Hepatitis C; The New Zealand Central Region Experience.	Lynnaire	Matthews
51	Hepatitis C: Towards Elimination in Community Opiate Treatment Programs, Bathurst Regional Hub.	Katherine	McQuillan
52	Enabling Hepatitis C (HCV) Treatment In Primary Care Through Community Based Fibroscan Assessment Clinics	James	O'Beirne
53	FIB-4 Is Highly Efficient At Excluding Cirrhosis In HCV -Validation Of A New Cut Off	James	O'Beirne
54	Efficacy And Safety Of Elbasvir/Grazoprevir In Women Infected With Hepatitis C Virus Genotype 1 Or 4 And Co-Administered Oral Contraceptives Or Hormone Replacement Therapy	Stefan	Orange
55	Global Scientific Strategy For An HBV Cure	Peter	Revill

Poster	Title	First Name	Last Name
56	Retrospective Analysis Of A Clinical Waitlist For Hepatitis C Treatment With All Oral Therapy In The Hunter New England Local Health District: Is The Warehouse Empty?	Suresh	Sharma
57	In Vitro Studies Identify A Low Replication Phenotype For Hepatitis B Virus Genotype H Generally Associated With Less Severe Liver Disease	Vitini	Sozzi
58	"CURE IT" Program- Curing Hepatitis C (HCV) Whilst Avoiding Hospital Attendance.	Hayley	Thompson
59	Nursing Model Of Care For Chronic Hepatitis B, In The Community - New Zealand, Explained. Explained by Hepatitis & Fibroscan Nurse of The Hepatitis Foundation NZ.	Jillian	White
60	Increasing Access To Hepatitis C Virus (HCV) Direct Acting Antivirals (DAAS) For South City Drug And Alcohol And Psychiatry Outpatients Of The Alfred Hospital Melbourne	Bradley	Whitton

2019

AVHEC





2019

Australasian Viral Hepatitis Elimination Conference 2019

Monday 5 - Tuesday 6 August 2019

Please mark the dates for the Australasian
Viral Hepatitis Elimination Conference 2019
in your diary and share this information
with colleagues.

Abstract Deadline: 7 April 2019

Early Bird Registration: 26 May 2019

Accommodation: 31 June 2019

Standard Registration: 21 July 2019

AVHEC Conference Secretariat

P: +61 2 8204 0770

F: +61 2 8204 0779

E: info@avhec2019.com

www.avhec2019.com



viral
HEPATITIS

www.hepatitis.org.au